A case presentation involving a patient with severe, symptomatic iliofemoral deep vein thrombosis and need for urgent ...

In this expert perspective, Manjot K. Gill, MD, discusses faricimab for the management of retinal vein occlusion.

The FDA has granted Priority Review status to Regeneron’s and Bayer’s supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The application seeks to expand use ...

In this expert perspective, Manjot K. Gill, MD, discusses the potential FDA approval in 2025 of aflibercept 8 mg for the treatment of retinal vein occlusion.

for aflibercept injection 8mg for the treatment of macular edema following retinal vein occlusion (RVO) and monthly dosing across all approved indications. The sBLA was supported by data from the ...

EYLEA HD is a treatment for retinal vein occlusion (RVO) that allows for dosing every 8 weeks after initial monthly doses, potentially halving injections. What is the FDA's action date for EYLEA ...

Regeneron on Thursday said the application covers Eylea HD for the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include monthly dosing ...

Considering taking supplements to treat retinal vein occlusion? Below is a list of common natural remedies used to treat or reduce the symptoms of retinal vein occlusion. Follow the links to read ...

In the presence of combined iliac vein obstruction and superficial or deep reflux, therefore, the emerging course of treatment is primarily to correct the obstructive component. When significant ...

At the J.P. Morgan Healthcare Conference in January, Regeneron CEO Leonard Schleifer said that the company’s new formulation of eye disease treatment Eylea needed “a few more arrows in its ...

An axial image of the abdomen and pelvis (Panel C) shows a nearly occlusive thrombus in the left renal vein and a nonocclusive thrombus in the right renal vein (arrows). Dr. Manning: The patient ...